Tekla Life Sciences Investors (HQL) Fundamentals 2026 — P/E 2.9x, Revenue Analysis | SniperIQ

9.61 on the NYSE. This SniperIQ fundamentals page covers Tekla Life Sciences Investors's valuation (P/E 2.9x, P/B 1.1x), profitability (net margin 331.9%), revenue ($86M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Tekla Life Sciences Investors's market cap?

Tekla Life Sciences Investors (HQL) has a market capitalization of approximately $596M, trading at

9.61 on the NYSE. Market cap moves with the live share price.

What is Tekla Life Sciences Investors's P/E ratio?

Tekla Life Sciences Investors's trailing twelve-month P/E ratio is 2.9x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Financial Services sector peers rather than read in isolation.

How profitable is Tekla Life Sciences Investors?

Tekla Life Sciences Investors runs a net profit margin of 331.9%, a gross margin of 90.7%, and an operating margin of 331.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Tekla Life Sciences Investors generate?

Tekla Life Sciences Investors reported revenue of $86M for fiscal year 2025, with net income of $86M and earnings per share (EPS) of 2.96. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Tekla Life Sciences Investors pay a dividend?

Tekla Life Sciences Investors offers a trailing dividend yield of about 10.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Tekla Life Sciences Investors financially healthy?

Tekla Life Sciences Investors carries a debt-to-equity ratio of 0.00x and a current ratio of 2.58x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Tekla Life Sciences Investors a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tekla Life Sciences Investors (HQL) the key facts are: market cap $596M, P/E 2.9x, revenue $86M, 52-week range 13.01-21.32. Weigh valuation, profitability, growth, and balance-sheet strength against Financial Services peers and form your own view.